Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.

Szczegóły

Tytuł:: Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Autorzy:: Chatzidimitriou C; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Pappa V; Second Propaedeutic Department of Internal Medicine and Research Institute, Hematology Unit, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece.
Lakiotaki E; First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Plata E; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Lafioniatis S; Haematology Unit, 'Achillopoulion' Hospital, Volos, Greece.
Angelopoulou MK; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Konstantopoulos K; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Korkolopoulou P; First Department of Pathology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Vassilakopoulos TP; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Źródło:: American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. 632-637. Date of Electronic Publication: 2021 Apr 02.
Typ publikacji:: Case Reports; Journal Article
Język:: English
Imprint Name(s):: Publication: New York Ny : Wiley-Blackwell
Original Publication: New York, Liss.
MeSH Terms:: Eosinophilia/*etiology
Hemorrhagic Disorders/*etiology
Mastocytosis, Systemic/*blood
Neoplasms, Second Primary/*blood
Pancytopenia/*etiology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*complications
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azacitidine/administration & dosage ; Azacitidine/therapeutic use ; Biomarkers, Tumor/blood ; Blood Cell Count ; Bone Marrow/pathology ; Cancer Survivors ; Chromosome Deletion ; Chromosome Disorders/pathology ; Chromosomes, Human, Pair 7 ; Diagnosis, Differential ; Eosinophilia/blood ; Hemorrhagic Disorders/blood ; Humans ; Interferon-alpha/therapeutic use ; Leukemia, Myeloid, Acute/pathology ; Male ; Mastocytosis, Systemic/complications ; Mastocytosis, Systemic/diagnosis ; Mastocytosis, Systemic/drug therapy ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/pathology ; Neoplasms, Second Primary/diagnosis ; Neoplasms, Second Primary/drug therapy ; Pancytopenia/blood ; Staurosporine/administration & dosage ; Staurosporine/analogs & derivatives ; Tryptases/blood
References:: Szczepański T, van der Velden VHJ, Waander E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol. 2011;29(12):1643-1649.
Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trialALL-BFM 95. Blood. 2008;111:4477-4489.
Tavernier E, Le Q-H, de Botton S, et al. Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer. 2007;110(12):2747-2755.
Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003;101:3386-3390.
Rai S, Espinoza JL, Morita Y, Tanaka H, Matsumura I. Severe eosinophilia in Myelodysplastic syndrome with a defined and rare cytogenetic abnormality. Front Immunol. 2019;9:3031.
Bakotic BW, Poniecka AW, Dominguez CJ, Benigno A, Donahue RP, Cabello-Inchausti B. Myelodysplastic syndrome with atypical eosinophilia in association with ring chromosome 7. A case report. Cancer Genet Cytogenet. 1999;115:19-22.
Wimazal F, Baumgartner C, Sonneck K, et al. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Invest. 2008;38(6):447-455.
Valent P, Klion D, Horny HP, et al. Contemporary consensus proposalon criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607-612.e9.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.
Swerdlow SH, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150-151.
Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727-5736.
Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-625.
Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769-3772.
Mital A, Prejzner W, Hellmann A. Acquired von Willebrand syndrome during systemic mastocytosis: an analysis of 21 cases. Pol Arch Intern Med. 2018;128(7-8):491-493.
Sucker C, Mansmann G, Steiner S, et al. Fatal bleeding due to a heparin-like anticoagulant in a 37- year old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost. 2008;14:360-364.
Black JS, Feldmann M, Leon S. Systemic mastocytosis as a rare cause of diffuse gastrointestinal hemorrhage. Am Surg. 2009;75:429-430.
Carvalhosa AB, Aouba AC, Damaj G. A French National Survey on clotting disorders in Mastocytosis. Medicine (Baltimore). 2015;94(40):e1414.
Thomas VA, Wheeless CJ, Stack MS, Johnson DA. Human mast celltryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry. 1998;37:2291-2298.
Prieto-Garcı'a A, Zheng D, Adachi R, et al. Mast cell restricted mouse and human tryptase heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen. J Biol Chem. 2012;287:7834-7844.
Maier M, Spragg JSL. Inactivation of human high molecular weight kininogen by human mast cell tryptase. J Immunol. 1983;130:2352-2356.
Hirokawa K, Aoki N. Up-regulation of thrombomodulin by activation of histamine H1-receptors in human umbilical-vein endothelial cells in vitro. Biochem J. 1991;276(Pt 3):739-743.
Lassila R, Lindstedt K, Kovanen PT. Native macromolecular heparin proteoglycans exocytosed from stimulated rat serosal mast cells strongly inhibit platelet-collagen interactions. Arterioscler Thromb Vasc Biol. 1997;17:3578-3587.
Alter SC, Kramps JA, Janoff A, Schwartz LB. Interactions of human mast cell tryptase with biological protease inhibitors. Arch Biochem Biophys. 1990;276:26-31.
Oscarsson LG, Pejler GLU. Location of the antithrombin-binding sequence in the heparin chain. J Biol Chem. 1989;264:296-304.
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Interferon-alpha)
EC 3.4.21.59 (Tryptases)
H88EPA0A3N (Staurosporine)
ID912S5VON (midostaurin)
M801H13NRU (Azacitidine)
SCR Disease Name:: Monosomy 7 of Bone Marrow
Entry Date(s):: Date Created: 20210227 Date Completed: 20210513 Latest Revision: 20210513
Update Code:: 20240105
DOI:: 10.1002/ajh.26145
PMID:: 33639008
: Czasopismo naukowe

Full Text Finder

Informacja